Literature DB >> 25218381

Sensitive and specific in situ hybridization for early drug discovery.

Pernille A Usher1, Elisabeth D Galsgaard, Kimberly Kruse, Jishu Wang, Berit O Krogh, Jette Mandelbaum, Kasper Almholt.   

Abstract

High-throughput analyses of gene expression such as microarrays and RNA-sequencing are widely used in early drug discovery to identify disease-associated genes. To further characterize the expression of selected genes, in situ hybridization (ISH) using RNA probes (riboprobes) is a powerful tool to localize mRNA expression at the cellular level in normal and diseased tissues, especially for novel drug targets, where research tools like specific antibodies are often lacking.We describe a sensitive ISH protocol using radiolabelled riboprobes suitable for both paraffin-embedded and cryo-preserved tissue. The riboprobes are generated by in vitro transcription using PCR products as templates, which is less time consuming compared to traditional transcription from linearized plasmids, and offers a relatively simple way to generate several probes per gene, e.g., for splice variant analyses. To ensure reliable ISH results, we have incorporated a number of specificity controls in our standard experimental setup. We design antisense probes to cover two non-overlapping parts of the gene of interest, and use the corresponding sense probes as controls for unspecific binding. Probes are furthermore tested on sections of paraffin-embedded or cryo-preserved positive and negative control cells with known gene expression. Our protocol thus provides a method for sensitive and specific ISH, which is suitable for target validation and characterization in early drug discovery.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25218381     DOI: 10.1007/978-1-4939-1459-3_10

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  1 in total

1.  Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.

Authors:  Kasper Almholt; Ole Didrik Lærum; Boye Schnack Nielsen; Ida Katrine Lund; Leif Røge Lund; John Rømer; Annika Jögi
Journal:  Clin Exp Metastasis       Date:  2015-06-04       Impact factor: 5.150

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.